Skip to main content
. 2022 Jul 9;6(4):pkac050. doi: 10.1093/jncics/pkac050

Figure 2.

Figure 2.

Cumulative survival probabilities by treatment and label change period and adjusted hazard ratios. aAdjusted for sex (female or male), smoking status (ever or never), race and ethnicity (Black, Latinx, White, other), primary site (bladder or nonbladder), age, body mass index, creatinine clearance, and calendar day of diagnosis. bHazard ratio comparing post- vs prelabel change within treatment group. CI = confidence interval; HR = hazard ratio; ICI = immune checkpoint inhibitors.